PMID- 34045898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung 
      Cancer: A Real-World Study.
PG  - 4115-4128
LID - 10.2147/CMAR.S304838 [doi]
AB  - BACKGROUND: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) 
      independently developed by China, which can inhibit tumor angiogenesis and tumor 
      cell proliferation. The ALTER 0303 study has suggested that anlotinib improved 
      overall survival (OS) and progression-free survival (PFS) in the treatment of 
      advanced non-small cell lung cancer (NSCLC). However, in the real world, the 
      efficacy and safety of anlotinib is not clear. Although relevant retrospective 
      studies have confirmed the efficacy and safety of anlotinib, the sample size is 
      small. And the OS was not observed because of the follow-up time was short. 
      Further studies are still essential to evaluate the efficacy and safety of 
      anlotinib in patients with advanced NSCLC in real-world settings. Related studies 
      have preliminarily shown that anlotinib combined with whole-brain radiotherapy 
      (WBRT) can significantly prolong the survival of patients with brain metastases 
      of NSCLC. This study also discusses the best treatment strategies of patients 
      with brain metastases. METHODS: A retrospective study was conducted on 206 
      patients with advanced NSCLC who had treated with anlotinib. The primary 
      endpoints were PFS and OS. The secondary endpoints were objective response rate 
      (ORR), disease control rate (DCR) and safety. Kaplan-Meier survival curves were 
      applied to evaluate the efficacy. Univariate analysis was performed by Log rank 
      testing. Cox regression analysis was utilized to evaluate the significance of 
      potential risk factors obtained from the univariate analysis. RESULTS: The median 
      PFS (mPFS) was 4.0 (95% CI: 3.607-4.393) months, univariate analysis revealed 
      that patients with longer PFS included epidermal growth factor receptor (EGFR) 
      mutation-negative, Eastern Cooperative Oncology Group performance status (ECOG 
      PS) </=1, no brain metastases, no liver metastases, no adrenal metastases, or </=2 
      distant metastases. Cox regression analysis indicated that patients with 
      EGFR-negative and ECOG PS </=1 had longer PFS. The median OS (mOS) was 8(95% CI: 
      6.495-9.505) months. EGFR mutation-negative, previous thoracic radiation therapy, 
      no brain metastases, or </=2 distant metastases were independent positive 
      predictors of OS. The results of Cox regression indicated that the patients 
      without previous thoracic radiation therapy (hazard ratio: 1.855; 95% CI: 
      1.162-2.960; p=0.010) had shortened OS. The objective response rate was 10.2%, 
      and the disease control rate was 78.2%. The main treatment-related adverse events 
      (AEs) were generally tolerated. All AEs observed during the trial were controlled 
      after dose reduction or symptomatic treatments, and no death was found to be 
      associated with anlotinib. CONCLUSION: Anlotinib was well tolerated and effective 
      in patients with advanced NSCLC. Patients with EGFR mutation-negative and ECOG PS 
      </=1 had longer PFS, and patients without previous thoracic radiation therapy (HR: 
      1.855, 95% CI 1.162-2.960; P = 0.010) had shorter OS. Further investigations are 
      needed because of small sample.
CI  - (c) 2021 Zhong and Liu.
FAU - Zhong, Qiuxia
AU  - Zhong Q
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China.
FAU - Liu, Zhihua
AU  - Liu Z
AD  - Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8149213
OTO - NOTNLM
OT  - advanced non-small cell lung cancer
OT  - anlotinib
OT  - efficacy
OT  - safety
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/05/29 06:00
MHDA- 2021/05/29 06:01
PMCR- 2021/05/20
CRDT- 2021/05/28 07:21
PHST- 2021/02/15 00:00 [received]
PHST- 2021/04/25 00:00 [accepted]
PHST- 2021/05/28 07:21 [entrez]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2021/05/29 06:01 [medline]
PHST- 2021/05/20 00:00 [pmc-release]
AID - 304838 [pii]
AID - 10.2147/CMAR.S304838 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 May 20;13:4115-4128. doi: 10.2147/CMAR.S304838. 
      eCollection 2021.